Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Keith Suckling

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Expert Opinion on Drug Discovery|March 14, 2013
What is the future for drug development in atherosclerosis and dyslipidaemia?Keith Suckling
Atherosclerosis|April 6, 2010
Phospholipase A2s: developing drug targets for atherosclerosisKeith Suckling
Expert Opinion on Drug Discovery|March 20, 2013
The ideal model in atherosclerosis and dyslipidaemia - does it exist?Keith Suckling
Expert Opinion on Therapeutic Targets|September 12, 2007
The continuing complexities of high-density lipoprotein metabolism in drug discovery and developmentKeith Suckling
Expert Opinion on Therapeutic Targets|May 17, 2007
Drug discovery in the metabolic syndrome: context and some recent developmentsKeith Suckling
Expert Opinion on Investigational Drugs|October 17, 2006
Discontinued drugs in 2005: cardiovascular drugsKeith Suckling
Expert Opinion on Therapeutic Patents|March 13, 2012
The landscape of drug discovery in atherosclerosis and dyslipidaemia revisited: an update of patenting activityKeith Suckling
Expert Opinion on Investigational Drugs|May 2, 2008
Selective thyromimetics for atherosclerosis and dyslipidaemia: another old target making progressKeith Suckling
Expert Opinion on Pharmacotherapy|April 22, 2008
The ENHANCE Study: an unusual publication of trial data raises questions beyond ezetimibeKeith Suckling
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Expert Opinion on Drug Discovery|March 14, 2013
What is the future for drug development in atherosclerosis and dyslipidaemia?Keith Suckling
Atherosclerosis|April 6, 2010
Phospholipase A2s: developing drug targets for atherosclerosisKeith Suckling
Expert Opinion on Drug Discovery|March 20, 2013
The ideal model in atherosclerosis and dyslipidaemia - does it exist?Keith Suckling
Expert Opinion on Therapeutic Targets|September 12, 2007
The continuing complexities of high-density lipoprotein metabolism in drug discovery and developmentKeith Suckling
Expert Opinion on Therapeutic Targets|May 17, 2007
Drug discovery in the metabolic syndrome: context and some recent developmentsKeith Suckling
Expert Opinion on Investigational Drugs|October 17, 2006
Discontinued drugs in 2005: cardiovascular drugsKeith Suckling
Expert Opinion on Therapeutic Patents|March 13, 2012
The landscape of drug discovery in atherosclerosis and dyslipidaemia revisited: an update of patenting activityKeith Suckling
Expert Opinion on Investigational Drugs|May 2, 2008
Selective thyromimetics for atherosclerosis and dyslipidaemia: another old target making progressKeith Suckling
Expert Opinion on Pharmacotherapy|April 22, 2008
The ENHANCE Study: an unusual publication of trial data raises questions beyond ezetimibeKeith Suckling
Pageof 1